EIF4E and diffuse large B-cell lymphoma: Additionally, in DLBCL cell lines lacking 4E-BPs (naturally or genetically edited), SBI-756 retained ability to inhibit eIF4F formation and sensitise to venetoclax, whereas the TOR-KI compound MLN0128 lacked activity in this setting.